Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas

Cancer Research

Volumn 61, Issue 19, 2001, Pages 7091-7100

  Nielsen, Boye Schnack ^a   Rank, Fritz ^b   López, José Manuel ^c   Balbin, Milagros ^d   Vizoso, Francisco ^e   Lund, Leif Røge ^a   Danø, Keld ^a   López Otín, Carlos ^d  

^a FINSEN LABORATORY   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF OVIEDO   (Spain)

^d DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^e HOSPITAL DE JOVE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; BIOCHEMICAL MARKER; CD31 ANTIGEN; CD68 ANTIGEN; COLLAGENASE 3; CYTOKERATIN; GELATINASE A; MATRIX METALLOPROTEINASE; MESSENGER RNA; STROMELYSIN 3;

ARTICLE; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ANALYSIS; ENZYME LOCALIZATION; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MACROPHAGE; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COLLAGENASES; DISEASE PROGRESSION; FEMALE; FIBROBLASTS; HUMANS; MATRIX METALLOPROTEINASE 13; NEOPLASM INVASIVENESS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035476863     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Plasminogen activators, tissue degradation and cancer
2. Cancer invasion and tissue remodeling - Cooperation of protease systems and cell types
3. Biology and biochemistry of proteinases in tumor invasion
4. Matrix metalloproteinases: Biologic activity and clinical implications
5. The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter
6. Mechanisms for pro matrix metalloproteinase activation
7. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity
8. Human MT6-matrix metalloproteinase: Identification, progelatinase A activation, and expression in brain tumors
9. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas
10. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules
11. Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor
12. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck
13. Collagenase-3 expression is associated with advanced local invasion in human squamous cell carcinomas of the larynx
14. Human collagenase-3 is expressed in malignant squamous epithelium of the skin
15. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas
16. Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas
17. Increased expression of collagenase-3 (MMP-13) and MTI-MMP in oesophageal cancer is related to cancer aggressiveness
18. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations
19. Collagenase-3 (matrix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic inflammation
20. Matrix metalloproteinases 2, 9, and 13, and tissue inhibitors of metalloproteinases 1 and 2 in experimental lung silicosis
21. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques
22. Expression of collagenase-3 (MMP-13) in human abdominal aortic aneurysms and vascular smooth muscle cells in culture
23. Functional overlap between two classes of matrix-degrading proteases in wound healing
24. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage
25. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis
26. Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium
27. Biochemical characterization of human collagenase-3
28. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of precollagenase-3
29. Fibrillin degradation by matrix metalloproteinases: Implications for connective tissue remodelling
30. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MTI-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme
31. Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase
32. Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors
33. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions
34. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response
35. Histological grading and prognosis in breast cancer
36. Ductal carcinoma in situ: A proposal for a new classification
37. r 72, 000 and 92, 000 type IV collagenases in human skin cancers by in situ hybridization
38. Co-ordinated expression of MMP-2 and its putative activator, MTI-MMP, in human placentation
39. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas
40. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas
41. Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues
42. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression
43. Invasive carcinoma - Usual histological types
44. Contraction of granulation tissue in vitro: Similarity to smooth muscle
45. The myofibroblast: A quarter century after its discovery
46. Cellular changes involved in conversion of normal to malignant breast: Importance of the stromal reaction
47. The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells
48. The plasticity of human breast carcinoma cells is more than epithelial to mesenchymal conversion
49. Identification, paracrine generation, and possible function of human breast carcinoma myofibroblasts in culture
50. Messenger RNA for urokinase plasminogen activator (uPA) is expressed in myofibroblasts adjacent to cancer cells in human breast cancer
51. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer
52. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis
53. Toward a rapid and sensitive in situ hybridization methodology using isotopic and nonisotopic probes
54. Preservation of RNA for in situ hybridization: Carnoy's versus formaldehyde fixation
55. One step sandwich enzyme immunoassays for human matrix metalloproteinase 13 (collagenase 3) using monoclonal antibodies
56. Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells
57. Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast
58. Basal cell-specific and hyperproliferation-related keratins in human breast cancer
59. Myoepithelial and basement membrane antigens in benign and malignant human breast tumors
60. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast
61. Expression of smooth muscle-specific proteins in myoepithelium and stromal myofibroblasts of normal and malignant human breast tissue
62. Detection of stromal invasion in breast cancer: The myoepithelial markers
63. Double immunolabeling with cytokeratin and smooth-muscle actin in confirming early invasive carcinoma of breast
64. Myoepithelial cells and basal lamina in poorly differentiated in situ duct carcinoma of the breast. An immunocytochemical study
65. Cytokines in human breast cancer: IL-1α and IL-1β expression
66. Gene expression and protein deposition of major basement membrane components and TGF-β1 in human breast cancer
67. Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: An in situ hybridization study
68. Collagenase-3 binds to a specific receptor and requires the low density lipoprotein receptor-related protein for internalization
69. Endo180, an endocytic recycling glycoprotein related to the macrophage mannose receptor is expressed on fibroblasts, endothelial cells and macrophages and functions as a lectin receptor
70. A urokinase receptor-associated protein with specific collagen binding properties
71. Stromal cell expression of components of matrix degrading protease systems in human cancer
72. Differential protease expression by cutaneous squamous and basal cell carcinomas
73. Cancer invasion and tissue remodeling: Common themes in proteolytic matrix degradation
74. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis
75. Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast